{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T14:25:21Z","timestamp":1770042321647,"version":"3.49.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81471358"],"award-info":[{"award-number":["81471358"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81771450"],"award-info":[{"award-number":["81771450"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2018YFC1314302"],"award-info":[{"award-number":["2018YFC1314302"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asian Journal of Psychiatry"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.ajp.2021.102741","type":"journal-article","created":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T11:17:06Z","timestamp":1624706226000},"page":"102741","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Rethinking olanzapine therapy for schizophrenia"],"prefix":"10.1016","volume":"62","author":[{"given":"Juanjuan","family":"Ren","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4071-1627","authenticated-orcid":false,"given":"Chen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajp.2021.102741_bib0005","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/0269881108089816","article-title":"Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial","volume":"23","author":"Afshar","year":"2009","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.ajp.2021.102741_bib0010","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1523\/JNEUROSCI.2656-12.2013","article-title":"Peptide inhibitors disrupt the serotonin 5-HT2C receptor interaction with phosphatase and tensin homolog to allosterically modulate cellular signaling and behavior","volume":"33","author":"Anastasio","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ajp.2021.102741_bib0015","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.neubiorev.2021.03.028","article-title":"The effect of antipsychotics on the cognitive performance of individuals with psychotic disorders: network meta-analyses of randomized controlled trials","volume":"126","author":"Baldez","year":"2021","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.ajp.2021.102741_bib0020","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.schres.2007.03.029","article-title":"Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial","volume":"93","author":"Baptista","year":"2007","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.ajp.2021.102741_bib0025","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s11883-010-0098-3","article-title":"Role of C-reactive protein in contributing to increased cardiovascular risk in metabolic syndrome","volume":"12","author":"Devaraj","year":"2010","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.ajp.2021.102741_bib0030","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.2147\/NDT.S202159","article-title":"Association between IL-6 and metabolic syndrome in schizophrenia patients treated with second-generation antipsychotics","volume":"15","author":"Fang","year":"2019","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.ajp.2021.102741_bib0035","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00213-013-3073-1","article-title":"A randomized, 12-week study of the effects of extended-release paliperidone (paliperidone ER) and olanzapine on metabolic profile, weight, insulin resistance, and \u03b2-cell function in schizophrenic patients","volume":"230","author":"Hu","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.ajp.2021.102741_bib0040","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/nm1349","article-title":"Disruption of PTEN coupling with 5-HT2C receptors suppresses behavioral responses induced by drugs of abuse","volume":"12","author":"Ji","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.ajp.2021.102741_bib0045","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archpsyc.64.6.633","article-title":"Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial","volume":"64","author":"Keefe","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.ajp.2021.102741_bib0050","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1017\/S109285291900124X","article-title":"Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities","volume":"24","author":"Krogmann","year":"2019","journal-title":"CNS Spectr."},{"key":"10.1016\/j.ajp.2021.102741_bib0055","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.schres.2012.09.019","article-title":"Relationship between metabolic syndrome and cognition in patients with schizophrenia","volume":"142","author":"Lindenmayer","year":"2012","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.ajp.2021.102741_bib0060","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0079-6123(08)00920-5","article-title":"PTEN-5-HT2C coupling: a new target for treating drug addiction","volume":"172","author":"Maillet","year":"2008","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.ajp.2021.102741_bib0065","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1176\/appi.ajp.2018.18030280","article-title":"Mitigation of olanzapine-induced weight gain with Samidorphan, an opioid antagonist: a randomized double-blind phase 2 study in patients with schizophrenia","volume":"176","author":"Martin","year":"2019","journal-title":"Am. J. Psychiatry"},{"issue":"Suppl. 1","key":"10.1016\/j.ajp.2021.102741_bib0070","first-page":"1","article-title":"Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review","volume":"19","author":"Newcomer","year":"2005","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ajp.2021.102741_bib0075","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.euroneuro.2005.04.009","article-title":"Size of burden of schizophrenia and psychotic disorders","volume":"15","author":"R\u00f6ssler","year":"2005","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.ajp.2021.102741_bib0080","doi-asserted-by":"crossref","first-page":"3732","DOI":"10.2174\/1381612821666150605111236","article-title":"Atypical antipsychotics and inverse agonism at 5-HT2 receptors","volume":"21","author":"Sullivan","year":"2015","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ajp.2021.102741_bib0085","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/wps.20252","article-title":"Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis","volume":"14","author":"Vancampfort","year":"2015","journal-title":"World Psychiatry"},{"key":"10.1016\/j.ajp.2021.102741_bib0090","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/wps.20614","article-title":"The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-review of meta-analyses of randomized controlled trials","volume":"18","author":"Vancampfort","year":"2019","journal-title":"World Psychiatry"},{"key":"10.1016\/j.ajp.2021.102741_bib0095","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.schres.2012.12.021","article-title":"A randomized controlled trial of olanzapine improving memory deficits in Han Chinese patients with first-episode schizophrenia","volume":"144","author":"Wang","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.ajp.2021.102741_bib0100","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1093\/ijnp\/pyaa001","article-title":"A novel synthetic interfering peptide Tat-3L4F attenuates olanzapine-induced weight gain through disrupting crosstalk between serotonin receptor 2C and protein phosphatase and tensin homolog in rats","volume":"23","author":"Wang","year":"2020","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.ajp.2021.102741_bib0105","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s00213-018-5136-9","article-title":"Effects of omega-3 fatty acids on metabolic syndrome in patients with schizophrenia: a 12-week randomized placebo-controlled trial","volume":"236","author":"Xu","year":"2019","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.ajp.2021.102741_bib0110","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.psyneuen.2017.04.014","article-title":"Metabolic adverse effects of olanzapine on cognitive dysfunction: a possible relationship between BDNF and TNF-alpha","volume":"81","author":"Zhang","year":"2017","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.ajp.2021.102741_bib0115","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s00213-018-4835-6","article-title":"Brain-derived neurotrophic factor as a biomarker for cognitive recovery in acute schizophrenia: 12-week results from a prospective longitudinal study","volume":"235","author":"Zhang","year":"2018","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.ajp.2021.102741_bib0120","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1177\/0269881118756062","article-title":"Dose reduction of risperidone and olanzapine can improve cognitive function and negative symptoms in stable schizophrenic patients: a single-blinded, 52-week, randomized controlled study","volume":"32","author":"Zhou","year":"2018","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.ajp.2021.102741_bib0125","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.3389\/fphar.2018.01393","article-title":"Topiramate and metformin are effective add-on treatments in controlling antipsychotic-induced weight gain: a systematic review and network meta-analysis","volume":"9","author":"Zhuo","year":"2018","journal-title":"Front. Pharmacol."}],"container-title":["Asian Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876201821001970?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876201821001970?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T16:39:38Z","timestamp":1761755978000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876201821001970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":25,"alternative-id":["S1876201821001970"],"URL":"https:\/\/doi.org\/10.1016\/j.ajp.2021.102741","relation":{},"ISSN":["1876-2018"],"issn-type":[{"value":"1876-2018","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rethinking olanzapine therapy for schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Asian Journal of Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajp.2021.102741","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102741"}}